A randomised double-blind placebo-controlled trial of prednisolone therapy in HBeAg and HBV DNA positive Chinese patients with chronic active hepatitis B
- 31 March 1991
- journal article
- clinical trial
- Published by Elsevier in Journal of Hepatology
- Vol. 12 (2) , 246-250
- https://doi.org/10.1016/0168-8278(91)90946-9
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- LONG-TERM FOLLOW-UP IN A RANDOMISED CONTROLLED TRIAL OF RECOMBINANT α2-INTERFERON IN CHINESE PATIENTS WITH CHRONIC HEPATITIS B INFECTIONThe Lancet, 1988
- Prednisone Withdrawal Followed by Recombinant Alpha Interferon in the Treatment of Chronic Type B HepatitisAnnals of Internal Medicine, 1988
- PLACEBO-CONTROLLED TRIAL OF RECOMBINANT α2-INTERFERON IN CHINESE HBsAg-CARRIER CHILDRENThe Lancet, 1987
- A pilot study on the effects of prednisone withdrawal on serum hepatitis B virus DNA and HBeAg in chronic active hepatitis BHepatology, 1986
- Prevention of maternal-infant hepatitis B virus transmission by immunization: The role of serum hepatitis B virus DNAHepatology, 1986
- A Short Course of Prednisolone in Chronic Type B HepatitisAnnals of Internal Medicine, 1986
- Comparative efficacy of adenine arabinoside 5′ monophosphate and prednisone withdrawal followed by adenine arabinoside 5′ monophosphate in the treatment of chronic active hepatitis type BGastroenterology, 1985
- Effects of short‐term, high‐dose prednisone treatment of patients with HBsAg‐positive chronic active hepatitisLiver International, 1985
- Seroconversion from Hepatitis B e Antigen to Antibody in Chronic Type B HepatitisAnnals of Internal Medicine, 1981
- Deleterious Effect of Prednisolone in HBsAg-positive Chronic Active HepatitisNew England Journal of Medicine, 1981